# Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine

## TL;DR

This study explores the awareness and use of DPD testing among Palestinian oncology professionals, revealing gaps in training and inconsistent practices.

## Contribution

The study provides insights into the current state of pharmacogenomics and DPD testing practices in Palestine.

## Key findings

- Over 70% of participants lack formal training in pharmacogenomics.
- Fewer than 50% screen for DPD deficiency before prescribing fluoropyrimidines.
- Standardized protocols and guidelines for DPD testing are lacking.

## Abstract

This study evaluated awareness, prevalence, and utilization of dihydropyrimidine dehydrogenase (DPD) testing and pharmacogenomics among oncologists, residents, and clinical pharmacists working in Palestinian hospitals.

This study aimed to assess the knowledge and opinions of HCPsspecializing in oncology in Palestine regarding screening for DPYD testing prior to prescribing FP.

A cross‐sectional survey was distributed to 106 HCPs across various hospitals in Palestine.

A notable deficiency in training and implementation of pharmacogenomics was observed, with over 70% of participants lacking formal training in the field. Although there is high awareness of DPD deficiency and its impact, fewer than 50% of participants screen for DPD deficiency prior to prescribing fluoropyrimidines (FP). Standardization and promotion of DPD testing are low, and guidelines for prescribing FP are lacking, leading to variations in clinical practice.

These findings highlight the need for enhanced training, standardized protocols, and increased awareness to improve patient safety and outcomes in cancer treatment in Palestine.